NCT03857854

Efficacy and Safety of Pirfenidone in Patient With Dermatomyositis Interstitial Lung Disease (Dm-ILD)

A Phase III, Randomized, Double-blind, Placebo Controlled, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Pirfenidone in Subjects With Dermatomyositis Interstitial Lung Disease (Dm-ILD)

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 152 (estimated)
• Sponsor: Beijing Continent Pharmaceutical Co, Ltd. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of pirfenidone in subjects with dermatomyositis interstitial lung disease

Conditions

• Dermatomyositis Interstitial Lung Disease (Dm-ILD)

Interventions

Type	Name	Description
DRUG	Pirfenidone	treatment group
DRUG	Placebos	placebo group

Timeline

• Start date: 2018-06-05
• Primary completion: 2021-02-01
• Completion: 2021-05-01
• First posted: 2019-02-28
• Last updated: 2019-02-28

Locations

1 site across 1 country: China